Summary

U.S. Attention Deficit Hyperactivity Disorder Market Summary

The U.S. attention deficit hyperactivity disorder market size was estimated at USD 10.31 billion in 2024 and is projected to reach USD 13.88 billion by 2033, growing at a CAGR of 3.3% from 2025 to 2033. The market is primarily driven by a continuous increase in diagnosed cases, supported by expanded diagnostic criteria, greater public awareness, and more consistent screening in primary care settings.

Attention Deficit Hyperactivity Disorder (ADHD) remains one of the most commonly diagnosed neurodevelopmental disorders in the U.S., shaping clinical practice and public health initiatives. A 2020-2022 National Health Interview Survey reported that 11.3% of U.S. children aged 5 to 17 have been diagnosed with ADHD at some point. Boys (14.5%) are nearly twice as likely as girls (8.0%) to receive a diagnosis. Similar trends are seen in adults, with lifetime ADHD prevalence estimated at around 8.1% among those aged 18 to 44.

Growing awareness among caregivers and educators, driven by school screening programs and destigmatization efforts, is further expanding the pool of patients being identified. Innovation in treatment options is another major driver of growth of the U.S. attention deficit hyperactivity disorder industry. Although stimulant medications such as methylphenidate and amphetamines continue to dominate prescriptions, recent advances highlight the market’s shift toward non-stimulant and digital therapies. In December 2023, the FDA expanded the indication for EndeavorRx, the first game-based digital therapeutic, to include adolescents aged 13 to 17, following pivotal STARS-ADHD trial data showing significant attention improvements on TOVA assessments (p < 0.0001).

Changes in care delivery and payer policies continue to influence market dynamics. The widespread adoption of telehealth, accelerated by the COVID-19 pandemic, has reduced barriers to ongoing treatment by facilitating more frequent follow-ups and dose adjustments. In addition, updated insurance coverage guidelines now commonly reimburse digital and behavioral therapies alongside medication. Integrated care models that combine behavioral therapy with medication management within pediatric and adolescent health networks are becoming increasingly prominent, especially as comorbid conditions such as anxiety and learning disorders receive greater attention. In January 2025, Supernus Pharmaceuticals obtained an FDA label update for Qelbree, adding new pharmacodynamic data and information on breastfeeding women.

M&A activity in the ADHD segment is relatively selective, primarily involving specialty pharmaceutical companies aiming to broaden their therapeutic or digital health portfolios. In September 2024, Collegium Pharmaceutical acquired Ironshore Therapeutics. The deal expanded Collegium's reach in the neurology sector, specifically in the ADHD market, and added Jornay PM, a stimulant to treat ADHD, to its portfolio.

U.S. Attention Deficit Hyperactivity Disorder Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. attention deficit hyperactivity disorder market report based on drug type, demographics, and distribution channel:

• Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
• Stimulants
• Amphetamine
• Methylphenidate
• Lisdexamfetamine
• Dexmethylphenidate
• Non-stimulants
• Atomoxetine
• Guanfacine
• Clonidine
• Others
• Demographics Outlook (Revenue, USD Million, 2021 - 2033)
• Children
• Adults
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Retail Pharmacy
• Hospital Pharmacy

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Type
1.2.2. Demographics
1.2.3. Distribution Channel
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Type Outlook
2.2.2. Demographics Outlook
2.2.3. Distribution Channel Outlook
2.3. Competitive Insights
Chapter 3. U.S. Attention Deficit Hyperactivity Disorder Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. U.S. Attention Deficit Hyperactivity Disorder Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
3.4. U.S. Attention Deficit Hyperactivity Disorder Market: Pipeline Analysis
Chapter 4. U.S. Attention Deficit Hyperactivity Disorder Market: Drug Type Estimates & Trend Analysis
4.1. Drug Type Segment Dashboard
4.2. U.S. Attention Deficit Hyperactivity Disorder Market: Drug Type Movement Analysis
4.3. U.S. Attention Deficit Hyperactivity Disorder Market Size & Trend Analysis, by Drug Type, 2021 - 2033 (USD Million)
4.4. Stimulants
4.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
4.4.2. Amphetamine
4.4.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
4.4.3. Methylphenidate
4.4.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
4.4.4. Lisdexamfetamine
4.4.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
4.4.5. Dexmethylphenidate
4.4.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
4.5. Non-stimulants
4.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
4.5.2. Atomoxetine
4.5.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
4.5.3. Guanfacine
4.5.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
4.5.4. Clonidine
4.5.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
4.5.5. Others
4.5.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
Chapter 5. U.S. Attention Deficit Hyperactivity Disorder Market: Demographics Estimates & Trend Analysis
5.1. Demographics Segment Dashboard
5.2. U.S. Attention Deficit Hyperactivity Disorder Market: Demographics Movement Analysis
5.3. U.S. Attention Deficit Hyperactivity Disorder Market Size & Trend Analysis, by Demographics, 2021 - 2033 (USD Million)
5.4. Children
5.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
5.5. Adults
5.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
Chapter 6. U.S. Attention Deficit Hyperactivity Disorder Market: Distribution Channel Estimates & Trend Analysis
6.1. Distribution Channel Segment Dashboard
6.2. U.S. Attention Deficit Hyperactivity Disorder Market: Distribution Channel Movement Analysis
6.3. U.S. Attention Deficit Hyperactivity Disorder Market Size & Trend Analysis, by Distribution Channel, 2021 - 2033 (USD Million)
6.4. Retail Pharmacy
6.4.1. Market Estimates and Forecasts 2021 - 2033 (USD million)
6.5. Hospital Pharmacy
6.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key company heat map analysis, 2024
7.4. Company Profiles
7.4.1. Lilly.
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Pfizer Inc.
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Johnson & Johnson
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Lupin Pharmaceuticals, Inc.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Novartis Pharmaceuticals Corporation
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Takeda Pharmaceutical Company Limited.
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Mallinckrodt.
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. PURDUE PHARMA L.P.
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. NEOS THERAPEUTICS, INC.
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Supernus Pharmaceuticals, Inc.
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives